Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19

NCT05813600 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Omicron Variant of COVID-19

Interventions

DRUG: Nirmatrelvir/Ritonavir

Sponsor

Xiangao Jiang